Publicaciones en las que colabora con Elías Campo Güerri (13)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  2. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO

    British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211

  3. Unraveling the genetics of transformed splenic marginal zone lymphoma

    Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709

2022

  1. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

    British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155

  2. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

    Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671

  3. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  4. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 589-598

2019

  1. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 3, pp. 576-586

2018

  1. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

    Leukemia, Vol. 32, Núm. 3, pp. 645-653

  2. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

    Leukemia, Vol. 32, Núm. 3, pp. 675-684

  3. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2016

  1. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia

    Blood, Vol. 127, Núm. 17, pp. 2122-2130

2013

  1. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

    Annals of Hematology, Vol. 92, Núm. 9, pp. 1151-1179